Join the Samuel Waxman Cancer Research Foundation in raising $50,000 for a grant to support research for Triple-Negative Breast Cancer, a subtype of breast cancer that targets young women, African-Americans, Latinas, Ashkenazi women and women with the BRCA1 mutation.
About Triple-Negative Breast Cancer:
Triple-Negative Breast Cancer – or TNBC – is a particularly aggressive subtype of breast cancer characterized by the lack of estrogen receptors, progesterone receptors, and HER2. Testing negative for all three means the cancer is triple-negative.
These negative results mean that the growth of the cancer is not supported by the hormones estrogen and progesterone, or by the presence of too many HER2 receptors.
Triple-negative breast cancer does not respond to hormonal therapy or therapies that target HER2 receptors.
Studies have shown that triple-negative breast cancer is more likely to spread beyond the breast and more likely to recur after treatment. These risks appear to be greatest in the first few years after treatment.
About Samuel Waxman Cancer Research Foundation:
The Samuel Waxman Cancer Research Foundation is a 38-year-old fundraising organization dedicated to eradicating cancer and developing less-toxic therapies for patients. Since its inception, the Foundation has raised over $85 million to fund more than 200 cancer researchers around the world. The foundation was a forerunner in the practice of scientists collaborating across research institutes to augment the impact of their work through shared findings. Currently, the Waxman Foundation counts leading institutes such as Dana-Farber, Mount Sinai, Weill-Cornell and MD Anderson among its many collaborators.
Watch our video to learn how our breakthrough collaborative approach to research has leveraged the expertise of the world's top cancer investigators!
About the research you’ll be supporting:
The Waxman Foundation is funding the work of four renowned scientists who are collaborating on research to make Triple-Negative Breast Cancer cells more responsive to hormonal treatment and reduce their ability to spread.
Our team of scientists is working from two leading research institutes: the Icahn School of Medicine at Mount Sinai in New York City and the Sylvester Comprehensive Cancer Center at the University of Miami. Our scientists at Mount Sinai include Eduardo Farias, Ph.D., Ming-Ming Zhou, Ph.D. and Samuel Waxman, M.D., founder and CEO of the Samuel Waxman Cancer Research Foundation. Their collaborator at the University of Miami is Arthur Zelent, Ph.D. The project also incorporates findings from SWCRF researchers Robert A. Weinberg, Ph.D., a founding member of the Whitehead Institute in Cambridge, MA, and Gregory David, Ph.D., of NYU Langone Medical Center in New York City.
|Samuel Waxman, M.D.||Ming-Ming Zhou, Ph.D.||Eduardo Farias Ph.D.||Arthur Zelent, Ph.D.|
|Icahn School of Medicine at Mount Sinai||Icahn School of Medicine at Mount Sinai||Icahn School of Medicine at Mount Sinai||University of Miami|
For a scientific summary of their project, click here.
Please donate today and remember to “Care & Share” by linking this page to your social media pages using the hashtag #LetsEndTNBC. Together, we can make a big difference in TNBC research, one donation at a time.
Please click here to donate today.